EULAR 14-17 June 2017 Madrid
Welcome to Roche at EULAR 2017
The European League Against Rheumatism (EULAR) annual congress attracts healthcare professionals, specialists and patient organisations working in the fields of rheumatology and musculoskeletal diseases. It is a yearly calendar highlight in the world of rheumatology providing the highest standards of scientific, educational and social exchange.
EULAR 2017 – June 14–17, Madrid, Spain
View Roche's highlights from this year's EULAR 2017 Congress, including Medical Booth materials, Roche-sponsored satellite symposia and published clinical trial data on multiple rheumatological disease areas.
Latest on Medically from EULAR 2017
From Evolution to Revolution in Treatment of RA Patients
Watch Prof. José María Álvaro-Gracia and a panel of leading Rheumatology experts as they evaluate the latest real-world evidence, new and existing treatment approaches for RA, presented in symposium at EULAR 2017.
A New ERA for Giant Cell Arteritis
Watch Prof. John. H. Stone and a panel of leading experts as they evaluate the latest in diagnosis and management of Giant Cell Arteritis, from symposium EULAR 2017
Evaluation of a dosing regimen for Tocilizumab in patients younger than two years of age with Systemic Juvenile Idiopathic Arthritis
Results of (NP25737) Phase I study evaluating the pharmacokinetics, pharmacodynamics, efficacy and safety of Tocilizumab in Systemic Juvenile Idiopathic Arthritis patients <2 years, presented at EULAR 2017.
The Tozura Study: a Pooled Analysis of Phase 4 Studies in 22 Countries
Subcutaneous Tocilizumab Monotherapy or Combined With a csDMARD in Patients With Rheumatoid Arthritis
The GiACTA Trial What Is the Optimal Dose of Tocilizumab for Giant Cell Arteritis?
Results from the GiACTA Phase III trial investigating the optimal dose of Tocilizumab for Giant Cell Arteritis, presented at EULAR 2017.
Clinical Trials in Rheumatic Diseases (Roche Medical Booth Material)
Learn about Roche's advancing scientific and clinical research in Rheumatic diseases.